Organoids as Oracles for Precision Medicine in Rectal Cancer

Kevin S Kolahi; Michitaka Nakano; Calvin J Kuo

doi:10.1016/j.stem.2019.12.003

Organoids as Oracles for Precision Medicine in Rectal Cancer

Cell Stem Cell. 2020 Jan 2;26(1):4-6. doi: 10.1016/j.stem.2019.12.003.

Authors

Kevin S Kolahi¹, Michitaka Nakano², Calvin J Kuo³

Affiliations

¹ Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
² Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA.
³ Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: [email protected].

PMID: 31951587
DOI: 10.1016/j.stem.2019.12.003

Abstract

Two recent papers in Cell Stem Cell and Nature Medicine (Yao et al. [2019] and Ganesh et al. [2019]) demonstrate the successful use of rectal cancer patient-derived organoids to predict patient responses to neoadjuvant chemoradiation therapy, paving the way toward a new paradigm for precision medicine.

Publication types

Comment

MeSH terms

Humans
Neoadjuvant Therapy
Organoids*
Precision Medicine
Rectal Neoplasms*